Literature DB >> 87616

Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.

A V Hoffbrand, A Gorman, M Laulicht, M Garidi, J Economidou, P Georgipoulou, M A Hussain, D M Flynn.   

Abstract

Subcutaneous desferrioxamine (2--4 g over 12 h) was administered 6 nights each week to 34 patients with transfusional iron overloads who continued to receive regular blood-transfusions. All 34 patients showed a fall in serum-ferritin after 5 to 12 months. In some patients serum-ferritin fell almost to normal. Liver function improved in all the patients, serum-aspartate-transaminase levels fell in all 17 patients tested, and liver-iron fell in 5 of 6 patients tested. These studies show that body-iron stores can be substantially reduced, to normal or near normal levels, by long-term subcutaneous desferrioxamine in patients with transfusional iron overload despite the need for continued blood-transfusion. They also show that removal of iron is accompanied by improved organ function.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87616     DOI: 10.1016/s0140-6736(79)91721-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Bone marrow transplantation for thalassaemia major.

Authors:  D I Evans
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

Review 2.  Plasma ferritin determination as a diagnostic tool.

Authors:  C A Finch; V Bellotti; S Stray; D A Lipschitz; J D Cook; M J Pippard; H A Huebers
Journal:  West J Med       Date:  1986-11

3.  Hepatitis B virus infection in thalassemia major.

Authors:  V Larcher; P Habibi; E Price
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-25

4.  Ocular changes in patients undergoing long-term desferrioxamine treatment.

Authors:  G B Arden; B Wonke; C Kennedy; E R Huehns
Journal:  Br J Ophthalmol       Date:  1984-12       Impact factor: 4.638

5.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

6.  Hepatic hemosiderosis in maintenance hemodialysis (MHD) patients.

Authors:  T Kothari; A P Swamy; J C Lee; J C Mangla; R V Cestero
Journal:  Dig Dis Sci       Date:  1980-05       Impact factor: 3.199

7.  Serum immunoreactive trypsin in beta-thalassaemia major.

Authors:  M Hussain; P Dandona; S S Fedail; L Ramdial; D Flynn; A V Hoffbrand
Journal:  J Clin Pathol       Date:  1981-09       Impact factor: 3.411

8.  Early iron overload in beta-thalassaemia major: when to start chelation therapy?

Authors:  S Fargion; M T Taddei; V Gabutti; A Piga; A Di Palma; L Capra; G Fontanelli; A Avanzini
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

9.  Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload.

Authors:  R W Chapman; M A Hussain; A Gorman; M Laulicht; D Politis; D M Flynn; S Sherlock; A V Hoffbrand
Journal:  J Clin Pathol       Date:  1982-05       Impact factor: 3.411

10.  Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

Authors:  M A Aldouri; B Wonke; A V Hoffbrand; D M Flynn; M Laulicht; L A Fenton; P J Scheuer; C C Kibbler; C A Allwood; D Brown
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.